Effects of coadministration of cannabinoids and morphine on nociceptive behaviour, brain monoamines and HPA axis activity in a rat model of persistent pain

European Journal of Neuroscience

Volumn 19, Issue 3, 2004, Pages 678-686

  Finn, D P ^a   Beckett, S R G ^a   Roe, C H ^a   Madjd, A ^a   Fone, K C F ^a   Kendall, D A ^a   Marsden, C A ^a   Chapman, V ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

9 tetrahydrocannabinol; Cannabidiol; Corticosterone; Formalin; Morphine

Indexed keywords

4 HYDROXY 3 METHOXYPHENYLETHYLENE GLYCOL; BRAIN MONOAMINE; CANNABIDIOL; CORTICOSTERONE; FORMALDEHYDE; MORPHINE; NORADRENALIN; SEROTONIN; TETRAHYDROCANNABINOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD SAMPLING; BRAIN; CONTROLLED STUDY; CORE TEMPERATURE; DRUG EFFECT; GROOMING; HYPOTHALAMUS; LOCOMOTION; LOW DRUG DOSE; MALE; METABOLITE; NOCICEPTION; NONHUMAN; PAIN; PRIORITY JOURNAL; RAT; TISSUE LEVEL;

ANIMALS; BEHAVIOR, ANIMAL; BIOGENIC MONOAMINES; BODY TEMPERATURE; BRAIN; BRAIN CHEMISTRY; CANNABIDIOL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CORTICOSTERONE; DISEASE MODELS, ANIMAL; DRUG INTERACTIONS; FORMALDEHYDE; MALE; MORPHINE; MOTOR ACTIVITY; NARCOTICS; PAIN; PAIN MEASUREMENT; PSYCHOTROPIC DRUGS; RADIOIMMUNOASSAY; RATS; TETRAHYDROCANNABINOL; TIME FACTORS;

EID: 1242317834     PISSN: 0953816X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0953-816X.2004.03177.x     Document Type: Article

References (65)

1. Abbott, F.V., Franklin, K.B.J. & Westbrook, R.F. (1995) The formalin test: Scoring properties of the first and second phases of the pain response in rats. Pain, 60, 91-102.
2. Baulmann, J., Spitznagel, H., Herdegen, T., Unger, T. & Culman, J. (2000) Tachykinin receptor inhibition and c-Fos expression in the rat brain following formalin-induced pain. Neuroscience, 95, 813-820.
3. Bisogno, T., Hanus, L., De Petrocellis, L., Tchilibon, S., Ponde, D.E., Brandi, I., Moriello, A.S., Davis, J.B., Mechoulam, R. & Di Marzo, V. (2001) Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br. J. Pharmacol., 134, 845-852.
4. Buckingham, J.C. & Cooper, T.A. (1984) Differences in hypothalamo-pituitary-adrenocortical activity in the rat after acute and prolonged treatment with morphine. Neuroendocrinology, 38, 411-417.
5. Cichewicz, D.L., Martin, Z.L., Smith, F.L. & Welch, S.P. (1999) Enhancement mu opioid antinociception by oral delta9-tetrahydrocannabinol: dose-response analysis and receptor identification. J. Pharmacol. Exp. Ther., 289, 859-867.
6. Cichewicz, D.L. & McCarthy, E.A. (2003) Antinociceptive synergy between delta (9)-tetrahydrocannabinol and opioids after oral administration. J. Pharmacol. Exp. Ther., 304, 1010-1015.
7. Clemett, D.A., Cockett, M.I., Marsden, C.A. & Fone, K.C. (1998) Antisense oligonucleotide-induced reduction in 5-hydroxytryptamine7 receptors in the rat hypothalamus without alteration in exploratory behaviour or neuroendocrine function. J. Neurochem., 71, 1271-1279.
8. Debreceni, L., Hartmann, G. & Debreceni, B. (1994) Effect of morphine on hypothalamic catecholamine and serotonin level in relation to the stress-induced pituitary-adrenocortical activation in the rat. Exp. Clin. Endocrinol., 102, 307-312.
9. Dubuisson, D. & Dennis, S.G. (1977) The formalin test: a quantitative study of the analgesic effects of morphine, meperidine, and brain stem stimulation in rats and cats. Pain, 4, 161-174.
10. Finn, D.P., Chapman, V., Jhaveri, M.D., Samanta, S., Manders, T., Bowden, J., Matthews, L., Marsden, C.A. & Beckett, S.R. (2003b) The role of the central nucleus of the amygdala in nociception and aversion. Neuroreport, 14, 981-984.
11. Finn, D.P., Jhaveri, M.D., Beckett, S.R.G., Kendall, D.A., Marsden, C.A., & Chapman, V. (2004) Cannabinoids modulate ultrasound-induced aversive responses in rats. Psychopharmacology (Berl.), [DOI: 10.1007/s00213-003-1629-1.] in press.
12. Finn, D.P., Jhaveri, M.D., Beckett, S.R.G., Roe, C.H., Kendall, D.A., Marsden, C.A. & Chapman, V. (2003a) Effects of direct periaqueductal grey administration of a cannabinoid receptor agonist on nociceptive and aversive responses in rats. Neuropharmacology, 45, 594-604.
13. Gao, X., Zhang, Y.Q., Zhang, L.M. & Wu, G.C. (2001) Effects of intraplantar injection of carrageenan on central dopamine release. Brain. Res. Bull., 54, 391-394.
14. Guimaraes, F.S., Chiaretti, T.M., Graeff, F.G. & Zuardi, A.W. (1990) Anti-anxiety effect of cannabidiol in the elevated plus-maze. Psychopharmacology (Berl.), 100, 558-559.
15. Heijna, M.H., Padt, M., Hogenboom, F., Schoffelmeer, A.N. & Mulder, A.H. (1991) Opioid-receptor-mediated inhibition of [3H]dopamine but not [3H]noradrenaline release from rat mediobasal hypothalamus slices. Neuroendocrinology, 54, 118-126.
16. Iyengar, S., Kim, H.S. & Wood, P.L. (1986) Kappa opiate agonists modulate the hypothalamic-pituitary-adrenocortical axis in the rat. J. Pharmacol. Exp. Ther., 238, 429-436.
17. Jarai, Z., Wagner, J.A., Varga, K., Lake, K.D., Compton, D.R., Martin, B.R., Zimmer, A.M., Bonner, T.I., Buckley, N.E., Mezey, E., Razdan, R.K., Zimmer, A. & Kunos, G. (1999) Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors. Proc. Natl Acad. Sci. USA, 96, 14136-14141.
18. 1 receptor antagonist SR-141716 in rats: open-field revisited. Pharmacol. Biochem. Behav., 73, 911-919.
19. Jezova, D., Vigas, M. & Jurcovicova, J. (1982) ACTH and corticosterone response to naloxone and morphine in normal, hypophysectomized and dexamethasone-treated rats. Life Sci., 31, 307-314.
20. Karniol, I.G. & Carlini, E.A. (1973) Pharmacological interaction between cannabidiol and delta 9-tetrahydrocannabinol. Psychopharmacology (Berl.), 33, 53-70.
21. Keay, K.A., Clement, C.I., Matar, W.M., Heslop, D.J., Henderson, L.A. & Bandler, R. (2002) Noxious activation of spinal or vagal afferents evokes distinct patterns of fos-like immunoreactivity in the ventrolateral periaqueductal gray of unanaesthetised rats. Brain Res., 948, 122-130.
22. Lichtman, A.H. & Martin, B.R. (1997) The selective cannabinoid antagonist SR 141716A blocks cannabinoid-induced antinociception in rats. Pharmacol. Biochem. Behav., 57, 7-12.
23. Liu, R.J., Qiang, M. & Qiao, J.T. (1998) Nociceptive c-fos expression in supraspinal areas in avoidance of descending suppression at the spinal relay station. Neuroscience, 85, 1073-1087.
24. Malfait, A.M., Gallily, R., Sumariwalla, P.F., Malik, A.S., Andreakos, E., Mechoulam, R. & Feldmann, M. (2000) The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis. Proc. Natl Acad. Sci. USA, 97, 9561-9566.
25. Manning, B.H. & Franklin, K.B. (1998) Morphine analgesia in the formalin test: reversal by microinjection of quaternary naloxone into the posterior hypothalamic area or periaqueductal gray. Behav. Brain. Res., 92, 97-102.
26. Martin, B.R., Compton, D.R., Thomas, B.F., Prescott, W.R., Little, P.J., Razdan, R.K., Johnson, M.R., Melvin, L.S., Mechoulam, R. & Ward, S.J. (1991) Behavioral, biochemical, and molecular modeling evaluations of cannabinoid analogs. Pharmacol. Biochem. Behav., 40, 471-478.
27. Martin-Calderon, J.L., Munoz, R.M., Villanua, M.A., del Arco, I., Moreno, J.L., RodrígueZ. de Fonseca, F. & Navarro, M. (1998) Characterization of the acute endocrine actions of (-)-11-hydroxy-Delta (8)-tetrahydrocannabinoldimethylheptyl (HU-210), a potent synthetic cannabinoid in rats. Eur. J. Pharmacol., 344, 77-86.
28. Moss, D.E. & Johnson, R.L. (1980) Tonic analgesic effects of Delta9-tetrahydrocannabinol as measured with the formalin test. Eur. J. Pharmacol., 61, 313-315.
29. Murphy, L.L., Steger, R.W., Smith, M.S. & Bartke, A. (1990) Effects of delta-9-tetrahydrocannabinol, cannabinol and cannabidiol, alone and in combinations, on luteinizing hormone and prolactin release and on hypothalamic neurotransmitters in the male rat. Neuroendocrinology, 52, 316-321.
30. Nicholson, B. (2003) Responsible prescribing of opioids for the management of chronic pain. Drugs, 63, 17-32.
31. Oluyomi, A.O., Hart, S.L. & Smith, T.W. (1992) Differential antinociceptive effects of morphine and methylmorphine in the formalin test. Pain, 49, 415-418.
32. Pacak, K., Palkovits, M., Kvetnansky, R., Yadid, G., Kopin, I.J. & Goldstein, D.S. (1995) Effects of various stressors on in vivo norepinephrine release in the hypothalamic paraventricular nucleus and on the pituitary-adrenocortical axis. Ann. NY Acad. Sci., 771, 115-130.
33. Palkovits, M., Baffi, J.S. & Pacak, K. (1999) The role of ascending neuronal pathways in stress-induced release of noradrenaline in the hypothalamic paraventricular nucleus of rats. J. Neuroendocrinol., 11, 529-539.
34. Parker, L.A., Mechoulam, R. & Schlievert, C. (2002) Cannabidiol, a non-psychoactive component of cannabis and its synthetic dimethylheptyl homolog suppress nausea in an experimental model with rats. Neuroreport, 13, 567-570.
35. Patel, S. & Hillard, C.J. (2001) Cannabinoid CB (1) receptor agonists produce cerebellar dysfunction in mice. J. Pharmacol. Exp. Ther., 297, 629-637.
36. Pertovaara, A., Bravo, R. & Herdegen, T. (1993) Induction and suppression of immediate-early genes in the rat brain by a selective alpha-2-adrenoceptor agonist and antagonist following noxious peripheral stimulation. Neuroscience, 54, 117-126.
37. Pertwee, R.G. (2001) Cannabinoid receptors and pain. Prog. Neurobiol., 63, 569-611.
38. Pertwee, R.G., Ross, R.A., Craib, S.J. & Thomas, A. (2002) (-)-cannabidiol antagonizes cannabinoid receptor agonists and noradrenaline in the mouse vas deferens. Eur. J. Pharmacol., 456, 99-106.
39. Plotsky, P.M. (1987) Facilitation of immunoreactive corticotrophin- releasing factor secretion into the hypophysial-portal circulation after activation of catecholaminergic pathways or central norepinephrine injection. Endocrinology, 121, 924-930.
40. Pugh, G. Jr, Smith, P.B., Dombrowski, D.S. & Welch, S.P. (1996) The role of endogenous opioids in enhancing the antinociception produced by the combination of delta 9-tetrahydrocannabinol and morphine in the spinal cord. J. Pharmacol. Exp. Ther., 279, 608-616.
41. Reche, I., Fuentes, J.A. & Ruiz-Gayo, M. (1996) Potentiation of delta 9-tetrahydrocannabinol-induced analgesia by morphine in mice: involvement of mu-and kappa-opioid receptors. Eur. J. Pharmacol., 318, 11-16.
42. Rodríguez de Fonseca, F., Rubio, P., Menzaghi, F., MerloPich, E., Rivier, J., Koob, G.F. & Navarro, M. (1996) Corticotropin-releasing factor (CRF) antagonist [D-Phe (12),Nle (21,38),C (alpha) MeLeu (37) ]CRF attenuates the acute actions of the highly potent cannabinoid receptor agonist HU-210 on defensive-withdrawal behavior in rats. J. Pharmacol. Exp. Ther., 276, 56-64.
43. Rodríguez de Fonseca, F., Villanua, M.A., Munoz, R.M., Sanmartinclark, O. & Navarro, M. (1995) Differential effects of chronic treatment with either dopamine D-1 or D-2 receptor agonists on the acute neuroendocrine actions of the highly potent synthetic cannabinoid Hu-210 in male rats. Neuroendocrinology, 61, 714-721.
44. Romero, E.M., Fernandez, B., Sagredo, O., Gomez, N., Uriguen, L., Guaza, C., De Miguel, R., Ramos, J.A. & Viveros, M.P. (2002) Antinociceptive, behavioural and neuroendocrine effects of CP 55,940 in young rats. Dev. Brain Res., 136, 85-92.
45. Sanders, J., Jackson, D.M. & Starmer, G.A. (1979) Interactions among the cannabinoids in the antagonism of the abdominal constriction response in the mouse. Psychopharmacology (Berl.), 61, 281-285.
46. Sañudo-Peña, M.C., Romero, J., Seale, G.E., Fernandez-Ruiz, J.J. & Walker, J.M. (2000) Activational role of cannabinoids on movement. Eur. J. Pharmacol., 391, 269-274.
47. Sawynok, J. & Reid, A. (1987) Effect of 6-hydroxydopamine-induced lesions to ascending and descending noradrenergic pathways on morphine analgesia. Brain Res., 419, 156-165.
48. Sevostianova, N., Zvartau, E., Bespalov, A. & Danysz, W. (2003) Effects of morphine on formalin-induced nociception in rats. Eur. J. Pharmacol., 462, 109-113.
49. Smith, F.L., Cichewicz, D., Martin, Z.L. & Welch, S.P. (1998) The enhancement of morphine antinociception in mice by delta9-tetrahydrocannabinol. Pharmacol. Biochem. Behav., 60, 559-566.
50. Sofia, R.D., Vassar, H.B. & Knobloch, L.C. (1975) Comparative analgesic activity of various naturally occurring cannabinoids in mice and rats. Psychopharmacologia, 40, 285-295.
51. Suemaru, S., Hashimoto, K. & Ota, Z. (1986) Effect of morphine on hypothalamic corticotropin-releasing factor (CRF) and pituitary-adrenocortical activity. Endocrinol. Jpn., 33, 441-448.
52. Tanaka, M., Tsuda, A., Yokoo, H., Yoshida, M., Mizoguchi, K. & Shimizu, T. (1991) Psychological stress-induced increases in noradrenaline release in rat brain regions are attenuated by diazepam, but not by morphine. Pharmacol. Biochem. Behav., 39, 191-195.
53. Taylor, B.K., Akana, S.F., Peterson, M.A., Dallman, M.F. & Basbaum, A.I. (1998) Pituitary-adrenocortical responses to persistent noxious stimuli in the awake rat: endogenous corticosterone does not reduce nociception in the formalin test. Endocrinology, 139, 2407-2413.
54. Thomas, B.F., Gilliam, A.F., Burch, D.F., Roche, M.J. & Seltzman, H.H. (1998) Comparative receptor binding analyses of cannabinoid agonists and antagonists. J. Pharmacol. Exp. Ther., 285, 285-292.
55. Tzavara, E.T., Perry, K.W., Rodriguez, D.E., Bymaster, F.P. & Nomikos, G.G. (2001) The cannabinoid CB (1) receptor antagonist SR141716A increases norepinephrine outflow in the rat anterior hypothalamus. Eur. J. Pharmacol., 426, R3-R4.
56. Wade, D.T., Robson, P., House, H., Makela, P. & Aram, J. (2003) A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms. Clin. Rehabilitation, 17, 21-29.
57. Wallace, M.J., Wiley, J.L., Martin, B.R. & DeLorenzo, R.J. (2001) Assessment of the role of CB1 receptors in cannabinoid anticonvulsant effects. Eur. J. Pharmacol., 428, 51-57.
58. Watson, G.S., Sufka, K.J. & Coderre, T.J. (1997) Optimal scoring strategies and weights for the formalin test in rats. Pain, 70, 53-58.
59. Welburn, P.J., Starmer, G.A., Chesher, G.B. & Jackson, D.M. (1976) Effect of cannabinoids on the abdominal constriction response in mice: within cannabinoid interactions. Psychopharmacologia, 46, 83-85.
60. Welch, S.P. & Eads, M. (1999) Synergistic interactions of endogenous opioids and cannabinoid systems. Brain Res., 848, 183-190.
61. Welch, S.P. & Stevens, D.L. (1992) Antinociceptive activity of intrathecally administered cannabinoids alone, and in combination with morphine, in mice. J. Pharmacol. Exp. Ther., 262, 10-18.
62. Welch, S.P., Thomas, C. & Patrick, G.S. (1995) Modulation of cannabinoid-induced antinociception after intracerebroventricular versus intrathecal administration to mice: possible mechanisms for interaction with morphine. J. Pharmacol. Exp. Ther., 272, 310-321.
63. Zhou, Y., Spangler, R., Maggos, C.E., Wang, X.M., Han, J.S., Ho, A. & Kreek, M.J. (1999) Hypothalamic-pituitary-adrenal activity and pro-opiomelanocortin mRNA levels in the hypothalamus and pituitary of the rat are differentially modulated by acute intermittent morphine with or without water restriction stress. J. Endocrinol, 163, 261-267.
64. Zuardi, A.W., Shirakawa, I., Finkelfarb, E. & Karniol, I.G. (1982) Action of cannabidiol on the anxiety and other effects produced by delta 9-THC in normal subjects. Psychopharmacology (Berl.), 76, 245-250.
65. Zuardi, A.W., Teixeira, N.A. & Karniol, I.C. (1984) Pharmacological interaction of the effects of delta 9-trans-tetrahydrocannabinol and cannabidiol on serum corticosterone levels in rats. Arch. Int. Pharmacodyn. Ther., 269, 12-19.